Back to Previous Page
Vietnam’s next structural growth story may not be technology or manufacturing—it could be healthcare
Vietnam’s pharmaceutical market is on track to surpass USD 10 billion, driven by a combination of powerful long-term trends rather than cyclical demand.
Three structural tailwinds stand out:
💊 An aging population. Vietnam is entering a demographic transition that will steadily increase demand for chronic disease treatment, specialty medicines, and healthcare services.
💊 Rising healthcare spending. As incomes continue to improve, consumers are allocating more toward quality healthcare, while insurance coverage and access to modern treatments continue to expand.
💊 Regulatory reforms. Recent policy changes are streamlining drug registration, encouraging domestic production, and making Vietnam a more attractive destination for pharmaceutical investment and manufacturing.
Vietnam’s pharmaceutical industry has traditionally been viewed as a defensive sector. But with the market expected to sustain high-single-digit growth over the coming years, the investment case is increasingly shifting toward structural growth.
As global supply chains diversify and Vietnam continues to strengthen its healthcare ecosystem, domestic pharmaceutical companies could benefit from both rising local demand and an improving regulatory environment.
Healthcare may not grab headlines as often as semiconductors or AI, but it could become one of Vietnam’s most durable long-term investment themes.
Original post from The Investor
You can further explore the potential of Vietnam’s healthcare sector in this video
